Elevated expression level of MicroRNA-196a is predictive of intestinal-type intraductal papillary mucinous neoplasm of the pancreas

Pancreas

Volumn 43, Issue 3, 2014, Pages 361-366

  Aso, Teppei ^a   Ohtsuka, Takao ^a   Tamura, Koji ^a   Ideno, Noboru ^a   Kono, Hiroshi ^a   Nagayoshi, Yosuke ^a   Ohuchida, Kennoki ^a   Ueda, Junji ^a   Takahata, Shunnichi ^a   Shindo, Koji ^a   Aishima, Shinichi ^a   Oda, Yoshinao ^a   Mizumoto, Kazuhiro ^a   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Intestinal type; IPMN; microRNA 196a

Indexed keywords

MICRORNA; MICRORNA 196A; UNCLASSIFIED DRUG; MIRN196 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOSCOPIC RETROGRADE PANCREATOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINAL TYPE INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MALE; MIDDLE AGED; PANCREAS; PANCREAS JUICE; PANCREATOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TISSUE LEVEL; YOUNG ADULT; ADENOCARCINOMA, MUCINOUS; ADENOCARCINOMA, PAPILLARY; CARCINOMA, PANCREATIC DUCTAL; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION REGULATION; GENETICS; INTESTINE; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC;

ADENOCARCINOMA, MUCINOUS; ADENOCARCINOMA, PAPILLARY; AGED; CARCINOMA, PANCREATIC DUCTAL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTESTINES; MALE; MICRORNAS; PANCREATIC JUICE; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84896669933     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000042     Document Type: Article

References (61)

1. Tanaka M. Controversies in the management of pancreatic IPMN. Nat Rev Gastroenterol Hepatol. 2011;8:56-60.
2. Falconi M, Salvia R, Bassi C, et al. Clinicopathological features and treatment of intraductal papillary mucinous tumour of the pancreas. Br J Surg. 2001;88:376-381.
3. Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183-197.
4. Tanaka M, Kobayashi K, Mizumoto K, et al. Clinical aspects of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol. 2005;40:669-675.
5. Sugiyama M, Atomi Y. Intraductal papillary mucinous tumors of the pancreas: Imaging studies and treatment strategies. Ann Surg. 1998;228:685-691.
6. Adsay N, Klöppel G, Fukushima N, et al. Intraductal papillary mucinous neoplasms of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, et al, eds. World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of the Digestive System. Lyon, France: IARC Press; 2010:304-313.
7. Furukawa T, Kloppel G, Volkan Adsay N, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: A consensus study. Virchows Arch. 2005;447:794-799.
8. Andrejevic-Blant S, Kosmahl M, Sipos B, et al. Pancreatic intraductal papillary-mucinous neoplasms: A new and evolving entity. Virchows Arch. 2007;451:863-869.
9. Adsay NV, Merati K, Basturk O, et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: Delineation of an ''intestinal'' pathway of carcinogenesis in the pancreas. Am J Surg Pathol. 2004;28:839-848.
10. Sadakari Y, Ohuchida K, Nakata K, et al. Invasive carcinoma derived from nonYintestinal type intraductal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from intestinal type. Surgery. 2010;147:812-817.
11. Mino-Kenudson M, Fernández-del Castillo C, Baba Y, et al. Prognosis of invasive IPMN depends on histological and precursor epithelial subtypes. Gut. 2011;60:1712-1720.
12. Furukawa T, Hatori T, Fujita I, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut. 2011;60:509-516.
13. Tsutsumi K, Ohtsuka T, Oda Y, et al. A history of acute pancreatitis in intraductal papillary mucinous neoplasms of the pancreas is a potential predictive factor for malignant papillary subtype. Pancreatology. 2011;10:707-712.
14. Aso T, Ohtsuka T, Ideno N, et al. Diagnostic significance of a dilated orifice of the duodenal papilla in intraductal papillary mucinous neoplasm of the pancreas. Gastrointest Endosc. 2012;76:313-320.
15. Hibi Y, Fukushima N, Tsuchida A, et al. Pancreatic juice cytology and subclassification of intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2007;34:197-204.
16. Ohuchida K, Mizumoto K, Ishikawa N, et al. A highly sensitive and quantitative telomerase activity assay with pancreatic juice is useful for diagnosis of pancreatic carcinoma without problems due to polymerase chain reaction inhibitors: Analysis of 100 samples of pancreatic juice from consecutive patients. Cancer. 2004;101:2309-2317.
17. Ohuchida K, Mizumoto K, Yamada D, et al. Quantitative analysis of MUC1 and MUC5AC mRNA in pancreatic juice for preoperative diagnosis of pancreatic cancer. Int J Cancer. 2006;118:405-411.
18. Ohuchida K, Mizumoto K, Ohhashi S, et al. Twist, a novel oncogene, is upregulated in pancreatic cancer: Clinical implication of Twist expression in pancreatic juice. Int J Cancer. 2007;120:1634-1640.
19. Ohuchida K, Mizumoto K, Yu J, et al. S100-6 is increased in a stepwise manner during pancreatic carcinogenesis: Clinical value of expression analysis in 98 pancreatic juice samples. Cancer Epidemiol Biomarkers Prev. 2007;16:649-654.
20. Sadakari Y, Ohtsuka T, Ohuchida K, et al. MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma. JOP. 2010;11:587-592.
21. Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs. Science. 2001;294:853-858.
22. Ambros V. The functions of animal microRNAs. Nature. 2004; 431:350-535.
23. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
24. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-838.
25. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065-7070.
26. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257-2261.
27. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26:4442-4452.
28. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297:1901-1908.
29. Habbe N, Koorstra JBM, Mendell JT, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther. 2009;8:340-346.
30. Nakahara O, Takamori H, Iwatsuki M, et al. Carcinogenesis of intraductal papillary mucinous neoplasm of the pancreas: Loss of microRNA-101 promotes overexpression of histone methyltransferase EZH2. Ann Surg Oncol. 2012;19:565-571.
31. Park YG, Lee KH, Lee JK, et al. MicroRNA expression pattern in intraductal papillary mucinous neoplasm. Korean J Gastroenterol. 2011;58:190-200.
32. Ryu JK, Matthaei H, Dal Molin M, et al. Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreatology. 2011;11:343-350.
33. Matthaei H, Wylie D, Lloyd MB, et al. miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res. 2012;18:4713-4724.
34. Maru DM, Singh RR, Hannah C, et al. MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol. 2009;174:1940-1948.
35. Kan T, Meltzer SJ. MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma. Curr Opin Pharmacol. 2009;9:727-732.
36. Luzna P, Gregar J, Uberall I, et al. Changes of microRNAs-192, 196a and 203 correlate with Barrett's esophagus diagnosis and its progression compared to normal healthy individuals. Diagn Pathol. 2077;6:114.
37. Schimanski CC, Frerichs K, Rahman F, et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol. 2009;18:2089-2096.
38. Zhan JF, Chen LH, Chen ZX, et al. A functional variant in microRNA-196-2 is associated with susceptibility of colorectal cancer in a Chinese population. Arch Med Res. 2011;42:144-148.
39. Tsutsumi K, Sato N, Cui L, et al. Expression of claudin-4 (CLDN4) mRNA in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol. 2011;24:533-541.
40. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-Time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408.
41. Silver N, Best S, Jiang J, et al. Selection of housekeeping genes for gene expression studies in human reticulocytes using real-Time PCR. BMC Mol Biol. 2006;7:33.
42. Ohuchida K, Mizumoto K, Lin C, et al. MicroRNA-10a is overexpressed in human pancreatic cancer and involved in its invasiveness partially via suppression of the HOXA1 gene. Ann Surg Oncol. 2012;19:2394-2402.
43. Nakata K, Ohuchida K, Mizumoto K, et al. MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis. Surgery. 2011;150:916-922.
44. Dillhoff M, Liu J, Frankel W, et al. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg. 2008;12:2171-2176.
45. Ryu JK, Hong SM, Karikari CA, et al. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology. 2010;10:66-73.
46. Ikenaga N, Ohuchida K, Mizumoto K, et al. MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol. 2010;17:3120-3128.
47. Papaconstantinou IG, Lykoudis PM, Gazouli M, et al. A review on the role of microRNA in biology, diagnosis, and treatment of pancreatic adenocarcinoma. Pancreas. 2012;41:671-677.
48. Papaconstantinou IG, Manta A, Gazouli M, et al. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas. 2013;42:67-71.
49. Kong X, Du Y, Wang G, et al. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: MiR-196a could be a potential marker for poor prognosis. Dig Dis Sci. 2011;56:602-609.
50. Ingkakul T, Sadakari Y, Ienaga J, et al. Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas. Ann Surg. 2010;251:70-75.
51. Tanno S, Nakano Y, Sugiyama Y, et al. Incidence of synchronous and metachronous pancreatic carcinoma in 168 patients with branch duct intraductal papillary mucinous neoplasm. Pancreatology. 2010;10:173-178.
52. Luthra R, Singh RR, Luthra MG, et al. MicroRNA-196a targets annexin A1: A microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 2008;27:6667-6678.
53. Sun M, Liu XH, Li JH, et al. MiR-196a is upregulated in gastric cancer and promotes cell proliferation by downregulating p27(kip1). Mol Cancer Ther. 2012;11:842-852.
54. Liu XH, Lu KH,Wang KM, et al. MicroRNA-196a promotes nonYsmall cell lung cancer cell proliferation and invasion through targeting HOXA5. BMC Cancer. 2012;12:348.
55. Mueller DW, Bosserhoff AK. MicroRNA miR-196a controls melanoma-Associated genes by regulating HOX-C8 expression. Int J Cancer. 2011;129:1064-1074.
56. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: An immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303-310.
57. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science. 2004;304:594-596.
58. Mansfield JH, Harfe BD, Nissen R, et al. MicroRNA-responsive 'sensor' transgenes uncover Hox-like and other developmentally regulated patterns of vertebrate microRNA expression. Nat Genet. 2004;36:1079-1083.
59. Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: A prospective multicenter study. Am J Gastroenterol. 2001;96:417-423.
60. Kanda M, Knight S, Topazian M, et al. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut. 2013;11:1024-1033.
61. Kanda M, Sadakari Y, Borges M, et al. Mutant TP53 in duodenal samples of pancreatic juice From patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol. 2013;11:719-30.